Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.The company also raised about $90 million in gross proceeds through at-the-market-facility.Vaxart is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.Vaxart shares were trading up 50.25% at $11.99 at the time of publication on Monday. The stock has a 52-week high of $14.30 and a 52-week low of 25 cents.Latest Ratings for VXRT DateFirmActionFromTo Jul 2020B. Riley FBRInitiates Coverage OnBuy Apr 2020HC Wainwright & Co.ReiteratesBuy Jun 2019H.C. WainwrightInitiates Coverage OnBuy View More Analyst Ratings for VXRT View the Latest Analyst RatingsSee more from Benzinga * 4 Cybersecurity Investment Opportunities Tied To The Rise In Online Threats * With E-Commerce Shift Underway, BofA Has High Expectations For PayPal's Q2 * Why Herbalife's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
